等待开盘 05-20 09:30:00 美东时间
-0.340
-3.57%
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
Goldman Sachs analyst Mark Delaney maintains Cerence (NASDAQ:CRNC) with a Neutral and raises the price target from $8 to $9.
05-09 01:48
Shares of Cerence (CRNC) fell 8% on Friday after the company reported second-quarter results. Cerence posted a Q2 GAAP EPS of $0.04. Revenue declined 17.7% year over year to $64.2M, though it beat an...
05-09 01:06
华盛资讯5月8日讯,Cerence Inc.公布2026财年Q1业绩,公司Q1营收0.64亿美元,同比下降17.9%,归母净利润0.02亿美元,同比下滑90.9%。
05-08 11:50
华盛资讯5月8日讯,Cerence Inc.公布2026财年Q2业绩,公司Q2营收0.64亿美元,同比下降17.7%,归母净利润0.02亿美元,同比下滑92.3%。
05-08 06:15
Cerence (NASDAQ:CRNC) is looking for Q3 GAAP EPS of $(0.02)-$0.07 vs $0.10 analyst estimate. sees sales of $68.000 million-$72.000 million vs $68.216 million analyst estimate.
05-08 04:23
https://storage.courtlistener.com/recap/gov.uscourts.txed.245499/gov.uscourts.txed.245499.1.0.pdf
05-05 22:58
Cerence Inc. has filed lawsuits against Amazon and its subsidiaries, alleging infringement of its intellectual property, particularly its voice technology patents. The complaints seek to block the import of Amazon's smart devices into the U.S. and address unauthorized use of Cerence's core technologies, which are integral to its conversational AI solutions. Cerence emphasizes its commitment to protecting its innovations and the value of its R&D i...
05-05 21:00
今日重点评级关注:Leerink Partners:维持Camp4 Therapeutics"跑赢大市"评级,目标价从8美元升至9美元;韦德布什:维持Arcus Biosciences"跑赢大市"评级,目标价从37美元升至41美元
04-06 16:27
Shares of companies within the broader technology sector are trading higher ami...
04-02 03:50